Debiopharm Group™ is a Swiss-based global bio-pharmaceutical group of companies with a focus on the development of innovative therapies and prescription drugs that target unmet medical needs.
Oncology is the group’s main area of expertise. In addition, Debiopharm Group™ develops or co-develops drugs for specific indications in other therapeutic areas such as infectious diseases, pain, metabolic diseases and immune-mediated diseases.
Debiopharm Group™'s core activities consist in:
- Licensing-in new molecules presenting potentially superior therapeutic properties, after a robust search and evaluation process
- Taking the licensed-in molecules through the entire development process, i.e. pre-clinical and clinical development, formulation, manufacturing and registration
- Selecting the best licensee(s) for the worldwide commercialisation of the registered drugs
Business Model
As a bridge between discovery and the market, Debiopharm transforms new molecules into registered drugs. More info
Partnering
Debiopharm has gained a great deal of experience with its partners (licensors and licensees) since its inception more than 30 years ago. More info
Pipeline
Debiopharm has a well balanced pipeline comprising products in every phase of development, with a special focus on oncology. More info
Expertise
Debiopharm possesses a broad expertise in-house and can rely on a vast network of external top consultants in all areas that are relevant to the development of drugs. More info
Products
Debiopharm’s work with molecules has resulted in the development of two successful compounds that have lead to five different products currently commercialised in most if not all markets in the world. More info
